Skip to main content


for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102. In addition the study will evaluate the safety of continued exposure to NKTR-102, observe disease status and survival status in subjects receiving NKTR-102, and evaluate the efficacy of NKTR-102 in subjects with advanced or metastatic solid tumors.

Official Title

An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies


Malignant Solid Tumor Open Label multicenter extension study advanced solid tumors


For people ages 18 years and up


  1. Received prior treatment with NKTR-102
  2. Free of disease progression since receiving NKTR-102
  3. Adequate bone marrow and organ function
  4. Treatment with NKTR-102 in the extension study to begin within 8 weeks after receipt of their of last dose of NKTR-102
  5. Agree to use adequate contraception


  1. Treatment with other anti-cancer therapy between the last dose of NKTR-102 in the prior study and before first dose of NKTR-102 in the extension study
  2. A toxicity that requires a 3rd dose reduction after taking NKTR-102 or are scheduled to receive a dose < 70 mg/m2 upon entry into this study
  3. Pregnancy or lactation


  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California, 94143, United States
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California, 90033, United States
  • Innovative Clinical Research Institute
    Whittier, California, 90603, United States


in progress, not accepting new patients
Start Date
Completion Date
Nektar Therapeutics
Phase 2
Lead Scientist
Pamela Munster
Study Type
Last Updated
October 5, 2017